Adaptors in toll-like receptor signaling and their potential as therapeutic targets

Current Drug Targets

Volumn 13, Issue 11, 2012, Pages 1360-1374

  Ve, Thomas ^a   Gay, Nicholas J ^b   Mansell, Ashley ^c   Kobe, Bostjan ^a   Kellie, Stuart ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adaptor proteins; TIR (Toll interleukin 1 receptor) domain; Toll like receptors (TLRs)

Indexed keywords

ADAPTOR PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOPLASM PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE DERIVATIVE; PROTEIN MAL; PROTEIN SARM; PROTEIN VIPER; RESATORVID; ST 2825; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 2; TRIPEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR;

ALLERGIC DISEASE; AUTOIMMUNE DISEASE; HUMAN; INFECTION; INFECTION SENSITIVITY; INFLAMMATORY DISEASE; INNATE IMMUNITY; NEOPLASM; NONHUMAN; PROTEIN DOMAIN; REGULATORY MECHANISM; REVIEW; SEPSIS; SIGNAL TRANSDUCTION;

DIMERIZATION; HUMANS; MODELS, MOLECULAR; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84866953674     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012803530260     Document Type: Review

References (191)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11(5): 373-84.
2. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem 2007; 76: 141-65.
3. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009; 9(8): 535-42.
4. Kang JY, Lee JO. Structural biology of the Toll-like receptor family. Annu Rev Biochem 2011; 80: 917-41.
5. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34(5): 637-50.
6. Coll RC, O'Neill LA. New insights into the regulation of signalling by toll-like receptors and nod-like receptors. J Innate Immun 2010; 2(5): 406-21.
7. Gay NJ, Gangloff M, O'Neill LA. What the Myddosome structure tells us about the initiation of innate immunity. Trends Immunol 2011; 32(3): 104-9.
8. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytokine. 2010; 49(3): 237-44.
9. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2(2): 253-8.
10. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998; 187(12): 2097-101.
11. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11(1): 115-22.
12. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000; 165(10): 5392-6.
13. Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleukin-1-and lipopolysaccharide-induced NF-kappaB activation by alternative splicing of MyD88. Curr Biol 2002; 12(6): 467-71.
14. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420(6913): 324-9.
15. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 1997; 7(6): 837-47.
16. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434(7034): 772-7.
17. Kawai T, Sato S, Ishii KJ, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 2004; 5(10): 1061-8.
18. Honda K, Yanai H, Mizutani T, et al. Role of a transductionaltranscriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 2004; 101(43): 15416-21.
19. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010; 465(7300): 885-90.
20. Avbelj M, Horvat S, Jerala R. The role of intermediary domain of MyD88 in cell activation and therapeutic inhibition of TLRs. J Immunol 2011; 187(5): 2394-404.
21. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197(2): 263-8.
22. He B, Santamaria R, Xu W, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 2010; 11(9): 836-45.
23. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420(6913): 329-33.
24. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001; 2(9): 835-41.
25. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413(6851): 78-83.
26. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 2006; 7(1): 49-56.
27. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2-and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 2009; 284(36): 24192-203.
28. Mansell A, Brint E, Gould JA, O'Neill LA, Hertzog PJ. Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem 2004; 279(36): 37227-30.
29. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O'Neill LA. MyD88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction. J Biol Chem 2006; 281(15): 10489-95.
30. Piao W, Song C, Chen H, et al. Tyrosine phosphorylation of MyD88 adapter-like (Mal) is critical for signal transduction and blocked in endotoxin tolerance. J Biol Chem 2008; 283(6): 3109-19.
31. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006; 7(2): 148-55.
32. Miggin SM, Palsson-McDermott E, Dunne A, et al. NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1. Proc Natl Acad Sci USA 2007; 104(9): 3372-7.
33. Ulrichts P, Bovijn C, Lievens S, Beyaert R, Tavernier J, Peelman F. Caspase-1 targets the TLR adaptor Mal at a crucial TIR-domain interaction site. J Cell Sci 2010; 123(Pt 2): 256-65.
34. Valkov E, Stamp A, Dimaio F, et al. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci USA 2011; 108(36): 14879-84.
35. Hoebe K, Du X, Georgel P, et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 2003; 424(6950): 743-8.
36. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003; 4(2): 161-7.
37. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301(5633): 640-3.
38. Funami K, Sasai M, Ohba Y, Oshiumi H, Seya T, Matsumoto M. Spatiotemporal mobilization of Toll/IL-1 receptor domaincontaining adaptor molecule-1 in response to dsRNA. J Immunol 2007; 179(10): 6867-72.
39. Funami K, Sasai M, Oshiumi H, Seya T, Matsumoto M. Homooligomerization is essential for Toll/interleukin-1 receptor domaincontaining adaptor molecule-1-mediated NF-kappaB and interferon regulatory factor-3 activation. J Biol Chem 2008; 283(26): 18283-91.
40. Tatematsu M, Ishii A, Oshiumi H, et al. A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation. J Biol Chem 2010; 285(26): 20128-36.
41. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferonbeta. J Biol Chem 2003; 278(50): 49751-62.
42. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol 2008; 9(4): 361-8.
43. Rowe DC, McGettrick AF, Latz E, et al. The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction. Proc Natl Acad Sci USA 2006; 103(16): 6299-304.
44. Mink M, Fogelgren B, Olszewski K, Maroy P, Csiszar K. A novel human gene (SARM) at chromosome 17q11 encodes a protein with a SAM motif and structural similarity to Armadillo/beta-catenin that is conserved in mouse, Drosophila, and Caenorhabditis elegans. Genomics 2001; 74(2): 234-44.
45. Meijer AH, Gabby Krens SF, Medina Rodriguez IA, et al. Expression analysis of the Toll-like receptor and TIR domain adaptor families of zebrafish. Mol Immunol 2004; 40(11): 773-83.
46. Couillault C, Pujol N, Reboul J, et al. TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat Immunol 2004; 5(5): 488-94.
47. Belinda LW, Wei WX, Hanh BT, Lei LX, Bow H, Ling DJ. SARM: a novel Toll-like receptor adaptor, is functionally conserved from arthropod to human. Mol Immunol 2008; 45(6): 1732-42.
48. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006; 7(10): 1074-81.
49. Peng J, Yuan Q, Lin B, et al. SARM inhibits both TRIF-and MyD88-mediated AP-1 activation. Eur J Immunol 2010; 40(6): 1738-47.
50. Chuang CF, Bargmann CI. A Toll-interleukin 1 repeat protein at the synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK signaling. Genes Dev 2005; 19(2): 270-81.
51. Kim Y, Zhou P, Qian L, et al. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med 2007; 204(9): 2063-74.
52. Chen CY, Lin CW, Chang CY, Jiang ST, Hsueh YP. Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology. J Cell Biol 2011; 193(4): 769-84.
53. Liberati NT, Fitzgerald KA, Kim DH, Feinbaum R, Golenbock DT, Ausubel FM. Requirement for a conserved Toll/interleukin-1 resistance domain protein in the Caenorhabditis elegans immune response. Proc Natl Acad Sci USA 2004; 101(17): 6593-8.
54. Zhang Q, Zmasek CM, Cai X, Godzik A. TIR domain-containing adaptor SARM is a late addition to the ongoing microbe-host dialog. Dev Comp Immunol 2011; 35(4): 461-8.
55. Okada T, Maeda A, Iwamatsu A, Gotoh K, Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 2000; 13(6): 817-27.
56. Inabe K, Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood 2002; 99(2): 584-9.
57. Troutman TD, Hu W, Fulenchek S, et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc Natl Acad Sci USA 2012; 109(1): 273-8.
58. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321(5889): 691-6.
59. Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine (Baltimore) 2010; 89(6): 403-25.
60. Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29(5): 746-57.
61. Nagpal K, Plantinga TS, Wong J, et al. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem 2009; 284(38): 25742-8.
62. George J, Motshwene PG, Wang H, et al. Two human MYD88 variants, S34Y and R98C, interfere with MyD88-IRAK4-myddosome assembly. J Biol Chem 2011; 286(2): 1341-53.
63. Adachi K, Tsutsui H, Kashiwamura S, et al. Plasmodium berghei infection in mice induces liver injury by an IL-12-and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol 2001; 167(10): 5928-34.
64. Scanga CA, Aliberti J, Jankovic D, et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002; 168(12): 5997-6001.
65. Edelson BT, Unanue ER. MyD88-dependent but Toll-like receptor 2-independent innate immunity to Listeria: no role for either in macrophage listericidal activity. J Immunol 2002; 169(7): 3869-75.
66. Muraille E, De Trez C, Brait M, De Baetselier P, Leo O, Carlier Y. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 2003; 170(8): 4237-41.
67. George J, Kubarenko AV, Rautanen A, et al. MyD88 adaptor-like D96N is a naturally occurring loss-of-function variant of TIRAP. J Immunol 2010; 184(6): 3025-32.
68. Song Z, Tong C, Sun Z, et al. Genetic variants in the TIRAP gene are associated with increased risk of sepsis-associated acute lung injury. BMC Med Genet 2010; 11: 168.
69. Ladhani SN, Davila S, Hibberd ML, et al. Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin-10 genes and susceptibility to invasive haemophilus influenzae serotype b infection in immunized children. Clin Infect Dis 2010; 51(7): 761-7.
70. Kumpf O, Giamarellos-Bourboulis EJ, Koch A, et al. Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Crit Care 2010; 14(3): R103.
71. Durrani O, Banahan K, Sheedy FJ, et al. TIRAP Ser180Leu polymorphism is associated with Behcet's disease. Rheumatology (Oxford) 2011; 50(10): 1760-5.
72. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39(4): 523-8.
73. Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 2008; 8(5): 541-4.
74. Nejentsev S, Thye T, Szeszko JS, et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet 2008; 40(3): 261-2;
75. Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha VV. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. Tuberculosis (Edinb) 2010; 90(5): 306-10.
76. Zhang YX, Xue Y, Liu JY, et al. Association of TIRAP (MAL) gene polymorhisms with susceptibility to tuberculosis in a Chinese population. Genet Mol Res 2011; 10(1): 7-15.
77. Miao R, Li J, Sun Z, Xu F, Shen H. Meta-analysis on the association of TIRAP S180L variant and tuberculosis susceptibility. Tuberculosis (Edinb) 2011; 91(3): 268-72.
78. Hamann L, Kumpf O, Schuring RP, et al. Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med Genet 2009; 10: 65.
79. Dissanayeke SR, Levin S, Pienaar S, et al. Polymorphic variation in TIRAP is not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some ethnic groups. PLoS One 2009; 4(8): e6698.
80. Sheedy FJ, Marinou I, O'Neill LA, Wilson AG. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann Rheum Dis 2008; 67(9): 1328-31.
81. Ramasawmy R, Cunha-Neto E, Fae KC, et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy. J Infect Dis 2009; 199(12): 1838-45.
82. Hawn TR, Dunstan SJ, Thwaites GE, et al. A polymorphism in Toll-interleukin 1 receptor domain containing adaptor protein is associated with susceptibility to meningeal tuberculosis. J Infect Dis 2006; 194(8): 1127-34.
83. Jeyaseelan S, Manzer R, Young SK, et al. Toll-IL-1 receptor domain-containing adaptor protein is critical for early lung immune responses against Escherichia coli lipopolysaccharide and viable Escherichia coli. J Immunol 2005; 175(11): 7484-95.
84. Jeyaseelan S, Young SK, Yamamoto M, et al. Toll/IL-1R domaincontaining adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudomonas aeruginosa. J Immunol 2006; 177(1): 538-47.
85. Jerke S, Srinivasan A, McSorley SJ. Expression of Toll/IL-1R domain-containing adaptor protein (TIRAP) is detrimental to primary clearance of Salmonella and is not required for the generation of protective immunity. Immunol Lett 2008; 116(1): 64-71.
86. Togbe D, Aurore G, Noulin N, et al. Nonredundant roles of TIRAP and MyD88 in airway response to endotoxin, independent of TRIF, IL-1 and IL-18 pathways. Lab Invest 2006; 86(11): 1126-35.
87. Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O'Neill LA. MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol 2009; 183(6): 3642-51.
88. Cole LE, Laird MH, Seekatz A, et al. Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling. J Leukoc Biol 2010; 87(2): 275-81.
89. Dong JW, Vallejo JG, Tzeng HP, Thomas JA, Mann DL. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 2010; 298(3): H1079-87.
90. Sakata Y, Dong JW, Vallejo JG, et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292(1): H503-9.
91. De Trez C, Pajak B, Brait M, et al. TLR4 and Toll-IL-1 receptor domain-containing adapter-inducing IFN-beta, but not MyD88, regulate Escherichia coli-induced dendritic cell maturation and apoptosis in vivo. J Immunol 2005; 175(2): 839-46.
92. Leichtle A, Hernandez M, Pak K, Webster NJ, Wasserman SI, Ryan AF. The toll-Like receptor adaptor TRIF contributes to otitis media pathogenesis and recovery. BMC Immunol 2009; 10: 45.
93. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005; 102(8): 2992-7.
94. Stack J, Haga IR, Schroder M, et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005; 201(6): 1007-18.
95. McAleer JP, Rossi RJ, Vella AT. Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF. J Immunol 2009; 182(9): 5322-30.
96. Sweeney TE, Suliman HB, Hollingsworth JW, Welty-Wolf KE, Piantadosi CA. A Toll-like receptor 2 pathway regulates the Ppargc1a/b metabolic co-activators in mice with Staphylococcal aureus sepsis. PLoS One 2011; 6(9): e25249.
97. Wang L, Trebicka E, Fu Y, et al. Regulation of lipopolysaccharideinduced translation of tumor necrosis factor-alpha by the toll-like receptor 4 adaptor protein TRAM. J Innate Immun 2011; 3(5): 437-46.
98. Szretter KJ, Samuel MA, Gilfillan S, Fuchs A, Colonna M, Diamond MS. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J Virol 2009; 83(18): 9329-38.
99. Dunzendorfer S, Lee HK, Soldau K, Tobias PS. Toll-like receptor 4 functions intracellularly in human coronary artery endothelial cells: roles of LBP and sCD14 in mediating LPS responses. FASEB J 2004; 18(10): 1117-9.
100. Lee HK, Dunzendorfer S, Tobias PS. Cytoplasmic domainmediated dimerizations of toll-like receptor 4 observed by betalactamase enzyme fragment complementation. J Biol Chem 2004; 279(11): 10564-74.
101. Burns K, Martinon F, Esslinger C, et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998; 273(20): 12203-9.
102. Ohnishi H, Tochio H, Kato Z, et al. Structural basis for the multiple interactions of the MyD88 TIR domain in TLR4 signaling. Proc Natl Acad Sci USA. 2009; 106(25): 10260-5.
103. Xu Y, Tao X, Shen B, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000; 408(6808): 111-5.
104. Nyman T, Stenmark P, Flodin S, Johansson I, Hammarstrom M, Nordlund P. The crystal structure of the human toll-like receptor 10 cytoplasmic domain reveals a putative signaling dimer. J Biol Chem 2008; 283(18): 11861-5.
105. Bernoux M, Ve T, Williams S, et al. Structural and functional analysis of a plant resistance protein TIR domain reveals interfaces for self-association, signaling, and autoregulation. Cell Host Microbe 2011; 9(3): 200-11.
106. Chan SL, Low LY, Hsu S, et al. Molecular mimicry in innate immunity: crystal structure of a bacterial TIR domain. J Biol Chem 2009; 284(32): 21386-92.
107. Chan SL, Mukasa T, Santelli E, Low LY, Pascual J. The crystal structure of a TIR domain from Arabidopsis thaliana reveals a conserved helical region unique to plants. Protein Sci 2010; 19(1): 155-61.
108. Bovijn C, Ulrichts P, De Smet AS, et al. Identification of interaction sites for dimerization and adapter recruitment in the Toll/Interleukin-1 receptor (TIR) domain of toll-like receptor 4. J Biol Chem 2012; 287(6): 4088-98.
109. Nunez Miguel R, Wong J, Westoll JF, et al. A dimer of the Tolllike receptor 4 cytoplasmic domain provides a specific scaffold for the recruitment of signalling adaptor proteins. PLoS One 2007; 2(8): e788.
110. Toshchakov VY, Szmacinski H, Couture LA, Lakowicz JR, Vogel SN. Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface. J Immunol 2011; 186(8): 4819-27.
111. Tao X, Xu Y, Zheng Y, Beg AA, Tong L. An extensively associated dimer in the structure of the C713S mutant of the TIR domain of human TLR2. Biochem Biophys Res Commun 2002; 299(2): 216-21.
112. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282(5396): 2085-8.
113. Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, Gay NJ. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J Biol Chem 2003; 278(42): 41443-51.
114. Jiang Z, Georgel P, Li C, et al. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci USA 2006; 103(29): 10961-6.
115. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989; 258(2): 301-4.
116. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membranebound proteins related to the IL-1 receptor. EMBO J 1994; 13(5): 1176-88.
117. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23(5): 479-90.
118. Coyle AJ, Lloyd C, Tian J, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999; 190(7): 895-902.
119. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998; 95(12): 6930-5.
120. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187(5): 787-94.
121. Brint EK, Xu D, Liu H, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol. 2004; 5(4): 373-9.
122. Basith S, Manavalan B, Govindaraj RG, Choi S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PLoS One 2011; 6(8): e23989.
123. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 1999; 11(6): 389-99.
124. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Tolllike receptor-interleukin 1 receptor signaling. Nat Immunol 2003; 4(9): 920-7.
125. Riva F, Polentarutti N, Tribbioli G, Mantovani A, Garlanda C, Turin L. The expression pattern of TIR8 is conserved among vertebrates. Vet Immunol Immunopathol 2009; 131(1-2): 44-9.
126. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009; 30(9): 439-46.
127. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor-and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005; 280(26): 25233-41.
128. Gong J, Wei T, Stark RW, et al. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: a computational approach. J Struct Biol 2010; 169(3): 323-30.
129. Lech M, Kulkarni OP, Pfeiffer S, et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008; 205(8): 1879-88.
130. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA 2004; 101(10): 3522-6.
131. Cirl C, Wieser A, Yadav M, et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008; 14(4): 399-406.
132. Newman RM, Salunkhe P, Godzik A, Reed JC. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect Immun 2006; 74(1): 594-601.
133. Salcedo SP, Marchesini MI, Lelouard H, et al. Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1. PLoS Pathog 2008; 4(2): e21.
134. Radhakrishnan GK, Yu Q, Harms JS, Splitter GA. Brucella TIR Domain-containing Protein Mimics Properties of the Toll-like Receptor Adaptor Protein TIRAP. J Biol Chem 2009; 284(15): 9892-8.
135. Yadav M, Zhang J, Fischer H, et al. Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence. PLoS Pathog 2010; 6(9): e1001120.
136. Sengupta D, Koblansky A, Gaines J, et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J Immunol 2010; 184(2): 956-64.
137. Radhakrishnan GK, Harms JS, Splitter GA. Modulation of microtubule dynamics by a TIR domain protein from the intracellular pathogen Brucella melitensis. Biochem J 2011; 439(1): 79-83.
138. Bahar MW, Graham SC, Chen RA, et al. How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 2011; 175(2): 127-34.
139. Graham SC, Bahar MW, Cooray S, et al. Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 2008; 4(8): e1000128.
140. Kalverda AP, Thompson GS, Vogel A, et al. Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 2009; 385(3): 843-53.
141. Cooray S, Bahar MW, Abrescia NG, et al. Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 2007; 88(Pt 6): 1656-66.
142. Gonzalez JM, Esteban M. A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 2010; 7: 59.
143. Oda S, Franklin E, Khan AR. Poxvirus A46 protein binds to TIR domain-containing Mal/TIRAP via an alpha-helical sub-domain. Mol Immunol 2011; 48(15-16): 2144-50.
144. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 2000; 97(18): 10162-7.
145. Loiarro M, Sette C, Gallo G, et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biol Chem 2005; 280(16): 15809-14.
146. Toshchakov VY, Fenton MJ, Vogel SN. Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. J Immunol 2007; 178(5): 2655-60.
147. Toshchakov VU, Basu S, Fenton MJ, Vogel SN. Differential involvement of BB loops of toll-IL-1 resistance (TIR) domaincontaining adapter proteins in TLR4-versus TLR2-mediated signal transduction. J Immunol 2005; 175(1): 494-500.
148. Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13(7): 933-40.
149. Takeuchi O, Sato S, Horiuchi T, et al. Cutting edge: role of Tolllike receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002; 169(1): 10-4.
150. Brown V, Brown RA, Ozinsky A, Hesselberth JR, Fields S. Binding specificity of Toll-like receptor cytoplasmic domains. Eur J Immunol 2006; 36(3): 742-53.
151. Lysakova-Devine T, Keogh B, Harrington B, et al. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptorlike and TRIF-related adaptor molecule. J Immunol 2010; 185(7): 4261-71.
152. Bartfai T, Behrens MM, Gaidarova S, Pemberton J, Shivanyuk A, Rebek J Jr. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci USA 2003; 100(13): 7971-6.
153. Loiarro M, Capolunghi F, Fanto N, et al. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol 2007; 82(4): 801-10.
154. Davis CN, Mann E, Behrens MM, et al. MyD88-dependent and-independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci USA 2006; 103(8): 2953-8.
155. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol 2011; 79(1): 34-41.
156. Vandepapeliere P, Horsmans Y, Moris P, et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26(10): 1375-86.
157. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anticancer vaccines: clinical results. Adv Exp Med Biol 2010; 667: 111-23.
158. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008; 4(5): 347-9.
159. Lacarrubba F, Nasca MR, Micali G. Advances in the use of topical imiquimod to treat dermatologic disorders. Ther Clin Risk Manag 2008; 4(1): 87-97.
160. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005; 152(5): 939-47.
161. Caperton C, Berman B. Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses. Clin Cosmet Investig Dermatol 2011; 4: 35-40.
162. Neubert T, Lehmann P. Bowen's disease-a review of newer treatment options. Ther Clin Risk Manag 2008; 4(5): 1085-95.
163. Bath-Hextall F, Bong J, Perkins W, Williams H. Interventions for basal cell carcinoma of the skin: systematic review. Bmj 2004; 329(7468): 705.
164. van Seters M, van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 2008; 358(14): 1465-73.
165. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30(2-3): 150-82.
166. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009; 61(3): 248-55.
167. Hussain I, Kline JN. CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. Curr Drug Targets Inflamm Allergy 2003; 2(3): 199-205.
168. Gupta GK, Agrawal DK. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. BioDrugs 2010; 24(4): 225-35.
169. Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009; 60: 279-91.
170. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004; 4(7): 512-20.
171. Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch Pharm Res 2009; 32(11): 1485-502.
172. Zhu J, Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010; 2010: 781235.
173. Hedayat M, Netea MG, Rezaei N. Targeting of Toll-like receptors: a decade of progress in combating infectious diseases. Lancet Infect Dis 2011; 11(9): 702-12.
174. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9(4): 293-307.
175. Cao Z, Hu Y, Wu W, et al. The TIR/BB-loop mimetic AS-1 protects the myocardium from ischaemia/reperfusion injury. Cardiovasc Res 2009; 84(3): 442-51.
176. Van Tassell BW, Seropian IM, Toldo S, et al. Pharmacologic inhibition of myeloid differentiation factor 88 (MyD88) prevents left ventricular dilation and hypertrophy after experimental acute myocardial infarction in the mouse. J Cardiovasc Pharmacol 2010; 55(4): 385-90.
177. Kissner TL, Moisan L, Mann E, et al. A small molecule that mimics the BB-loop in the Toll interleukin-1 (IL-1) receptor domain of MyD88 attenuates staphylococcal enterotoxin B-induced pro-inflammatory cytokine production and toxicity in mice. J Biol Chem 2011; 286(36): 31385-96.
178. Loiarro M, Ruggiero V, Sette C. Targeting TLR/IL-1R signalling in human diseases. Mediators Inflamm 2010; 2010: 674363.
179. Kuno M, Nemoto K, Ninomiya N, et al. The novel selective tolllike receptor 4 signal transduction inhibitor tak-242 prevents endotoxaemia in conscious Guinea-pigs. Clin Exp Pharmacol Physiol 2009; 36(5-6): 589-93.
180. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007; 571(2-3): 231-9.
181. Sha T, Iizawa Y, Ii M. Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis. Shock 2011; 35(2): 205-9.
182. Rice TW, Wheeler AP, Bernard GR, et al. A randomized, doubleblind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38(8): 1685-94.
183. Suzuki N, Suzuki S, Duncan GS, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature. 2002; 416(6882): 750-6.
184. Kawagoe T, Sato S, Matsushita K, et al. Sequential control of Tolllike receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008; 9(6): 684-91.
185. Wan Y, Xiao H, Affolter J, et al. Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated posttranscriptional control. J Biol Chem 2009; 284(16): 10367-75.
186. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7(8): 758-65.
187. Meylan E, Burns K, Hofmann K, et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5(5): 503-7.
188. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 2004; 101(10): 3533-8.
189. Yamamoto M, Yamazaki S, Uematsu S, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 2004; 430(6996): 218-22.
190. Sasai M, Tatematsu M, Oshiumi H, et al. Direct binding of TRAF2 and TRAF6 to TICAM-1/TRIF adaptor participates in activation of the Toll-like receptor 3/4 pathway. Mol Immunol 2010; 47(6): 1283-91.
191. O'Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003; 24(6): 286-90.